Clinical trials: sponsored by Boehringer Ingelheim
Healthy
A Study in Healthy Men to Test How the Body Takes up and Tolerates Different Doses of BI 765080
The main objectives of this trial are to investigate safety, tolerability, and pharmacokinetics of BI 765080 in healthy male subjects following intravenous administration of single rising doses.
- Trial name
- NCT04666922
- Testing
- BI 765080
- Where
- Belgium
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Test the Influence of BI 1323495 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood
The main objectives of this trial are to investigate the relative bioavailabilities of rosuvastatin (Reference 1, Part 1) and dabigatran (Reference 2, Part 2) given alone and together with BI 1323495 (Test 1, Test 2) following…
- Trial name
- NCT04257032
- Testing
- Rosuvastatin, Rosuvastatin + BI 1323495, Dabigatran etexilate
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
The purpose of this research study is to evaluate the efficacy and safety of an empagliflozin dosing regimen and one dose of linagliptin in patients with type 2 diabetes who are aged 10 to below 18 years and are currently taking…
- Trial name
- NCT03429543
- Testing
- Metformin, Insulin, Linagliptin
- Where
- 83 sites in United States, Argentina and 12 more
- Volunteers
- 175 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1323495 in the Blood
The main objective of this trial is to investigate the relative bioavailability of BI 1323495 in plasma when given as oral single dose together with multiple oral doses of itraconazole (Test,T) as compared to when given alone as…
- Trial name
- NCT04011241
- Testing
- BI 1323495, Itraconazole
- Where
- Germany
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
This Study in Healthy Men Tests How Different Doses of BI 1323495 Are Taken up in the Body and How Well They Are Tolerated.
The primary objective of this trial is to investigate the safety and tolerability of BI 1323495 in healthy male subjects following oral administration of single rising doses.
- Trial name
- NCT03588390
- Testing
- BI 1323495
- Where
- Germany
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men and Women to Test How Well Different Doses of BI 1323495 Are Tolerated
The primary objective of this trial is to investigate the safety and tolerability of BI 1323495 in healthy subjects following bid oral administration of multiple rising doses, each over an 11 day treatment period.
- Trial name
- NCT04107805
- Testing
- BI 1323495, Midazolam
- Where
- Germany
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Test How BI 1595043 is Taken up in the Body When Given With or Without Food
The main objective of this trial is to investigate the relative bioavailability of BI 1595043 under fed state (Test, T) and under fasted state (Reference, R).
- Trial name
- NCT04789291
- Testing
- BI 1595043
- Where
- Belgium
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study to Test How Food Influences the Amount of BI 1323495 in the Blood of Healthy Men
The main objective of this trial is to assess the effect of food on the pharmacokinetics of an oral tablet formulation of BI 1323495 by investigating the relative bioavailability following single dose administration under fed and…
- Trial name
- NCT03802331
- Testing
- BI 1323495,
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Test How Different Doses of BI 1595043 Are Tolerated
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1595043 in healthy male subjects following oral administration of single rising doses.
- Trial name
- NCT04439838
- Testing
- BI 1595043
- Where
- Belgium
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study to Test How Healthy Men Tolerate Different Doses of BI 1595043
The primary objectives of this trial are to investigate safety and tolerability of BI 1595043 in healthy male subjects following administration of multiple rising doses over 14 days.
- Trial name
- NCT04789304
- Testing
- BI 1595043, Midazolam
- Where
- Belgium
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Lung Diseases, Interstitial
A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis
The main objective is to assess long term safety of treatment with oral nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD).
- Trial name
- NCT03313180
- Testing
- Nintedanib
- Where
- 159 sites in United States, Argentina and 28 more
- Volunteers
- 444 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes
The primary research question is to evaluate whether, among patients with type 2 diabetes mellitus (T2D), initiation of empagliflozin changes the adjusted incidence of outcomes compared with initiation of Glucagon-Like Peptide-1…
- Trial name
- NCT03993132
- Testing
- Empagliflozin, Liraglutide
- Where
- Denmark
- Volunteers
- 26,774 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations
The primary objective of this exploratory meta-analysis is to evaluate the frequencies, incidence rates, and hazard ratios of lower-limb amputation (LLA) events (primary outcome) and of adverse events related to amputation…
- Trial name
- NCT04937816
- Testing
- Empagliflozin
- Where
- Germany
- Volunteers
- 16,746 people
- Sponsor
- Boehringer Ingelheim
Borderline Personality Disorder
A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder
This study is open to adults with borderline personality disorder. The purpose of this study is to find out whether a medicine called BI 1358894 helps to reduce symptoms in people with borderline personality disorder.
- Trial name
- NCT04566601
- Testing
- BI 1358894
- Where
- 67 sites in United States, Argentina and 13 more
- Volunteers
- 390 people
- Sponsor
- Boehringer Ingelheim
Lung Diseases, Interstitial (in Pediatric Populations), Childhood Interstitial Lung Disease (chILD)
A Treatment Protocol to Support the Care of Children and Adolescents With Fibrosing Interstitial Lung Disease (ILD)
This Expanded Access Program (EAP) is intended to facilitate the availability of OFEV® (nintedanib) to children and adolescents with chronic fibrosing interstitial lung disease (ILD) on top of current standard of care treatment…
- Trial name
- NCT05624281
- Testing
- nintedanib
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Japanese Men to Test How Well Different Doses of BI 765845 Are Tolerated
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 765845 in healthy male Japanese subjects following intravenous administration of single rising doses.
- Trial name
- NCT06139341
- Testing
- BI 765845
- Where
- Japan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment
Identifying biomarkers to predict the clinical course and benefits of therapy early in the course of the disease remains one of the most urgent and relevant challenges to improve overall patient management, to prevent treatment…
- Trial name
- NCT02788474
- Testing
- nintedanib
- Where
- 86 sites in United States, Australia and 11 more
- Volunteers
- 347 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Proof of Concept Study Assessing Technology-Assisted Respiratory Adherence Prototype Version 3 in Individuals With COPD
The study's primary aim is to assess whether there is a clinically significant reduction in breathlessness in symptomatic individuals with chronic obstructive respiratory disease (IwCOPD) following engagement with…
- Trial name
- NCT04795323
- Testing
- TARA v3.1, only non-pharmacological self-management support, TARA v3.2, both non-pharmacological and pharmacological self-management support
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin
This is a study in Chinese adults with type 2 diabetes. The study is open to people who take insulin but still have too high blood sugar levels. Participants may additionally be taking up to 2 other medicines for their diabetes.
- Trial name
- NCT04233801
- Testing
- Empagliflozin
- Where
- 24 sites in China
- Volunteers
- 219 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive, Asthma
Evaluation of the Respimat Inhaler vs. a HFA MDI Using Berodual in Patients With COPD With Poor MDI Technique.
The objective of this trial is to compare the total and regional deposition of aerosol in the lungs and oropharynx of patients with COPD and known poor MDI inhalation technique following inhalation of Berodual delivered via the…
- Trial name
- NCT00267917
- Testing
- Berodual Respimat, Berodual HFA-MDI
- Where
- Germany
- Volunteers
- 13 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.